



RECEIVED

JAN 28 2002

TECH CENTER 1600/2900 PATENT
DOCKET NO.: 2283/301

#22 JP
1/28/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant :	Leivan DeVeylder et al)	Examiner:
)	C. Collins
Serial No. :	09/574,735)	
)	Art Unit:
Conf. No. :	1507)	1638
)	
Filed :	May 18, 2000)	
)	
For :	CYCLIN-DEPENDENT KINASE INHIBITORS)	
	AND USES THEREOF)	

RESPONSE TO RESTRICTION REQUIREMENT
UNDER 37 C.F.R. § 1.111 AND § 1.143

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the Office Action dated November 15, 2001, and in accordance with the provisions of 37 C.F.R. § § 1.111 and 1.143, Applicants provisionally elect, with traverse, the subject matter of Group IV, claims 2, 5, 7-25, 27-31 and 36-57, drawn to methods comprising introducing into a plant cell a nucleic acid molecule of SEQ ID NO:1 encoding a cyclin-dependent kinase inhibitor (CKI) of SEQ ID NO:2, and to transgenic plants comprising said nucleotide sequence.

REMARKS

Claims 1-59 are present in the application and have been subjected to restriction by the Examiner under 35 U.S.C. § 121 (37 C.F.R. 1.142) as follows:

I. Claims 1, 3, 4, 6, 12, 26, 29, 34, 52, and 54, drawn to methods in a plant, comprising introducing into a plant cell a cyclin-dependent kinase inhibitor (CKI) of SEQ ID NO:2, classified in class 435, subclass 410;

II. Claims 1, 3, 4, 6, 12, 26, 28, 29, 34, 52, and 54, drawn to methods comprising introducing into a plant cell a cyclin-dependent kinase inhibitor (CKI) of SEQ ID NO: 4, classified in class 435, subclass 410;

G186477.1